Purchase Order VA580N18616
- Not listed
- This is a firm fixed-price purchase order contract awarded by the Department of Veterans Affairs (VA) to Regenesis Biomedical Inc., a for-profit medical technology company. The $4,820.98 contract is for the Provant Therapy System, a patented non-invasive regenerative medicine product indicated for post-operative pain and edema treatment. The contract was awarded under Regenesis Biomedical's existing General Services Administration (GSA) Schedule 65-II-A contract for medical equipment and...
- This is a firm fixed-price purchase order contract awarded by the Department of Veterans Affairs (VA) to Regenesis Biomedical Inc., a private medical technology company. The $3,698.05 contract is for the provision of Regenesis Biomedical's proprietary Provant Therapy System, a non-invasive regenerative medicine product indicated for the palliative treatment of post-operative pain and edema. The contract was not set aside for any preferential contracting vehicle. Regenesis Biomedical has been...
- This is a firm fixed-price purchase order awarded by the Department of Veterans Affairs (VA) to Regenesis Biomedical Inc., a privately held medical technology company. The contract is for the provision of Regenesis Biomedical's proprietary Provant Therapy System, a noninvasive regenerative medicine product indicated for the palliative treatment of post-operative pain and edema. The contract has a ceiling value of $7,231.47 and was awarded on May 24, 2011, with a completion date of June 24, 2011....
- This is a firm fixed-price purchase order contract awarded by the Department of Veterans Affairs (VA), specifically the Veterans Integrated Service Network 17, to Regenesis Biomedical Inc., a for-profit manufacturer of medical goods. The $7,142.85 contract is for the provision of Regenesis Biomedical's Provant Therapy System, a patented noninvasive regenerative medicine product, for the palliative treatment of post-operative pain and edema. The contract does not utilize any set-aside...
- This is a firm fixed-price purchase order contract awarded by the Department of Veterans Affairs (VA) to Regenesis Biomedical Inc. for the Provant Therapy System, a non-invasive regenerative medicine product. The contract has a ceiling value of $3,675.14 and a completion date of August 12, 2011. Regenesis Biomedical is the prime contractor and manufacturer of the Provant Therapy System, which is indicated for the palliative treatment of post-operative pain and edema. The contract was awarded...
- This is a firm fixed-price purchase order awarded by the Veterans Integrated Service Network 17 (VISN 17) of the U.S. Department of Veterans Affairs (VA) to Regenesis Biomedical Inc., a manufacturer of medical devices. The $4,820.98 contract is for the provision of Regenesis Biomedical's Provant Therapy System, a non-invasive regenerative medicine product indicated for the palliative treatment of post-operative pain and edema. The contract does not utilize any set-aside designations. Regenesis...
- This is a federal contract award from the U.S. Department of Veterans Affairs (VA) to Regenesis Biomedical Inc., a medical technology company. The $3,738.60 firm fixed-price purchase order is for Regenesis Biomedical's Provant Therapy System, a non-invasive regenerative medicine product indicated for post-operative pain and edema treatment. The contract has no set-aside designation and is being issued through Regenesis Biomedical's existing GSA Schedule 65-II-A contract for medical equipment and...
- This is a $3,645.14 firm fixed-price purchase order awarded by the Department of Veterans Affairs (VA) to Regenesis Biomedical Inc. for the Provant Therapy System, a noninvasive regenerative medicine product. The contract is not set-aside and was awarded under Regenesis Biomedical's existing GSA Schedule 65-II-A contract for medical equipment and supplies. The Provant Therapy System is indicated for palliative treatment of post-operative pain and edema, and Regenesis Biomedical appears to be the...
- This is a firm fixed-price purchase order awarded by the Department of Veterans Affairs (VA) to Regenesis Biomedical Inc., a privately held medical technology company. The $4,820.98 contract is for the Provant Therapy System, a noninvasive regenerative medicine product developed and patented by Regenesis Biomedical. The Provant Therapy System is indicated for the palliative treatment of post-operative pain and edema. The contract has an ultimate completion date of March 16, 2011. Regenesis...
- This is a $4,882.79 firm fixed-price purchase order contract awarded by the Department of Veterans Affairs (VA) to Regenesis Biomedical Inc., a for-profit medical device manufacturer. The contract is for the provision of Regenesis Biomedical's Provant Therapy System, a non-invasive regenerative medicine product indicated for the palliative treatment of post-operative pain and edema. The contract was awarded on December 14, 2010, with a completion date of January 14, 2011. No set-aside was...
This is a firm fixed-price purchase order contract awarded by the U.S. Department of Veterans Affairs (VA) to Regenesis Biomedical Inc., a medical device manufacturer. The contract, valued at $3,645.14, is for the provision of Regenesis Biomedical's Provant Therapy System, a non-invasive regenerative medicine product indicated for the palliative treatment of post-operative pain and edema. The contract does not have a set-aside designation. Regenesis Biomedical Inc. is the prime contractor and appears to be the sole provider of the Provant Therapy System under this contract, without any major subcontractors involved. The contract was awarded through the VA's General Services Administration (GSA) Schedule 65-II-A for medical equipment and supplies, indicating that Regenesis Biomedical Inc. has an existing GSA Schedule contract to facilitate the sale of its Provant Therapy System to the VA and other government agencies.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $3.6k | 12/10/10 |